Pharmacokinetic evaluation of eltoprazine

Bibliography

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision. Am Psychiatry Assoc. Washington, DC; 2000
   Google Scholar
• Hawi Z, Dring M, Kirely A, Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT1B receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry 2002;7:718-25
   PubMed Web of Science ®Google Scholar
• Jensen PS, Hinshaw SP, Kraemer HC, ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-58
   PubMed Web of Science ®Google Scholar
• Mayes SD, Calhoun SL, Chase GA, ADHD subtypes and co-occurring anxiety, depression, and oppositional-defiant disorder: differences in Gordon Diagnostic System and Wechsler Working Memory and Processing Speed Index Scores. J Atten Disord 2009;12:540-50
   PubMed Web of Science ®Google Scholar
• Retz W, Rosler M, Ose C, Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkely R, The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler R, Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9
   PubMed Web of Science ®Google Scholar
• Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med 2010;122:69-77
   PubMed Web of Science ®Google Scholar
• Eltoprazine HCl Investigator's Brochure. PsychoGenics, Inc. Tarrytown, NY; 2010
   Google Scholar
• Wigal SB, Wigal TL. Special considerations in diagnosing and treating attention-deficit/hyperactivity disorder. Prim Psychiatry 2007;12:1-14
   Google Scholar
• Niederhofer H. An open trial of buspirone in the treatment of attention-deficit disorder. Hum Psychopharmacol Clin Exp 2003;18:489-92
   PubMed Web of Science ®Google Scholar
• Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010;122:97-109
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL, Kollins SH. Advances in methylphenidate drug delivery systems for ADHD therapy. Advances in ADHD 2006;1:4-7
   Google Scholar
• Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005;90:i26-9
   PubMed Web of Science ®Google Scholar
• Strattera medication guide. Eli Lilly and Co., Indianapolis, IN; 2003
   Google Scholar
• Jain R, Segal S, Kollins SH, Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:171-9
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2011;127(6), doi:10.1542/peds.2010-1260
   Google Scholar
• Sallee FR, McGough J, Wigal T, Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Roessner V, Dittmann RW, Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13:102-16
   PubMed Web of Science ®Google Scholar
• Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1385-90
   PubMed Web of Science ®Google Scholar
• LaHoste GJ, Swanson JM, Wigal SB, D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996;3:38-41
   Google Scholar
• Li D, Sham PC, Owen MJ, Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006;15:2276-84
   PubMed Web of Science ®Google Scholar
• Quist JF, Barr CL, Schachar R, The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Mol Psychiatry 2003;8:98-102
   PubMed Web of Science ®Google Scholar
• Lesch KP, Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law 2000;18:581-604
   PubMed Web of Science ®Google Scholar
• Olivier B, Oorschot, R. 5-HT1B receptors and aggression: a review. Eur J Pharmacol 2005;526:207-17
   PubMed Web of Science ®Google Scholar
• Raghoebar M, Mak M, Cournot A, Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. Br J. Clin Pharmacol 1990;30:879-83
   Google Scholar
• Olivier B, Mos J, Rasmussen D. Behavioural pharmacology of the serenic, eltoprazine. Drug Metab Interac 1990;8(1-2):31-83
   PubMedGoogle Scholar
• PGI 12001 Clinical study report. The effects of eltoprazine on symptoms of attention deficit hyperactivity disorder (ADHD) in adults: a double-blind, multiple-dose, crossover, safety and preliminary efficacy trial. Tarrytown, NY;PsychoGenics, Inc. 2008
   Google Scholar
• van den Bergh F, Westphal K, Bloemarts E, Eltoprazine, a serotonin1A/1B receptor agonist, resembles D-amphetamine on different measures of impulsivity. Targeting Impulsivity. Wageningen: Ponsen & Looijen, 2006
   Google Scholar
• Verdonk ML, Kanters JA, Kroon J. Structure of eltoprazine. Acta Cryst 1992;C48:2271-3
   Google Scholar
• Schipper J, Tulp MT, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metab Interact 1990;8(1-2):85-114
   PubMedGoogle Scholar
• Ybema CE, Slangen JL, Olivier B, Discriminative stimulus properties of the serotonergic compound eltoprazine. J Pharmacol Exp Ther 1992;260:1045-51
   PubMed Web of Science ®Google Scholar
• de Vries MH, de Koning P, Floot HL, Dose-proportionality of eltoprazine: Pharmacokinetics of single oral doses in healthy subjects. Eur J Clin Pharmacol 1991;41:485-8
   PubMed Web of Science ®Google Scholar
• Sheiner L, Beal S. Evaluation of methods for estimating population pharmacokinetic parameters. J Pharmacokinet Biopharm 1980;8:553-71
   PubMedGoogle Scholar
• de Koning P, Mak M, de Vries MH, Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study. Inter Clin Psychopharmacol 1994;9:187-94
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006;10:92-111
   PubMedGoogle Scholar